IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
Lin, MaoFang1; Hou, Jian2; Chen, WenMing3; Huang, XiaoJun4; Liu, ZhuoGang5; Zhou, YuHong6; Li, Yan7; Zhao, Taiyun8; Wang, LinNa8; Wu, Kwang-Wei8; Shen, ZhiXiang9
关键词Bortezomib Chinese Multiple Myeloma Observational Study Refractory Relapsed Response
刊名ADVANCES IN THERAPY
2014-10-01
DOI10.1007/s12325-014-0159-z
31期:10页:1082-1094
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental ; Pharmacology & Pharmacy
研究领域[WOS]Research & Experimental Medicine ; Pharmacology & Pharmacy
关键词[WOS]DEXAMETHASONE ; EPIDEMIOLOGY ; STRATEGIES ; PARADIGMS ; RISK
英文摘要

Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patients with different ethnic backgrounds. The efficacy and safety of bortezomib was assessed in patients from China with relapsed/refractory MM in a real-world scenario.

This prospective, non-interventional, observational study enrolled both male and female Chinese patients, aged a parts per thousand yen18 years and diagnosed with relapsed or refractory MM. Administration of intravenous bortezomib at 1.3 mg/m(2) was recommended twice a week for 2 weeks (days 1, 4, 8 and 11), followed by a 10-day rest period (maximum of 8 cycles) and a follow-up every 12 weeks for 3 years. Efficacy assessments included best response, objective response rate (ORR), time to response, duration of response, and overall survival. Safety was also assessed.

A total of 517 patients were enrolled with a median age of 58.7 years. Patients predominantly had immunoglobulin G type (46.2%) and stage III (47.8%) myeloma. Overall, 202 (42.3%) patients had partial response as best response, ORR was 88.9% and the proportion of patients exhibiting complete response was 24.7%. The median time to response observed was 27 (21-40) days. Median time to progression was 415 days and median overall survival was 475 days. Thrombocytopenia (14.4%) was the most common adverse event.

Bortezomib demonstrated clinical response in majority of patients and was well tolerated in this observational study in Chinese patients with relapsed/refractory MM.

语种英语
WOS记录号WOS:000344322000005
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50086
专题北京大学第二临床医学院
北京大学第二临床医学院_血液科
作者单位1.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China
2.Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China
3.Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
4.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
5.China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China
6.Zhejiang Prov Tradit Chinese Med Hosp, Dept Hematol, Shenyang, Liaoning, Peoples R China
7.China Med Univ, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China
8.Xian Janssen Pharmaceut Co, Beijing, Peoples R China
9.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
推荐引用方式
GB/T 7714
Lin, MaoFang,Hou, Jian,Chen, WenMing,et al. Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients[J]. ADVANCES IN THERAPY,2014,31(10):1082-1094.
APA Lin, MaoFang.,Hou, Jian.,Chen, WenMing.,Huang, XiaoJun.,Liu, ZhuoGang.,...&Shen, ZhiXiang.(2014).Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients.ADVANCES IN THERAPY,31(10),1082-1094.
MLA Lin, MaoFang,et al."Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients".ADVANCES IN THERAPY 31.10(2014):1082-1094.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lin, MaoFang]的文章
[Hou, Jian]的文章
[Chen, WenMing]的文章
百度学术
百度学术中相似的文章
[Lin, MaoFang]的文章
[Hou, Jian]的文章
[Chen, WenMing]的文章
必应学术
必应学术中相似的文章
[Lin, MaoFang]的文章
[Hou, Jian]的文章
[Chen, WenMing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。